Endometrial Carcinoma Following Treatment for Breast Carcinoma in a Nigerian Female. A Case Report and Review of the Literature

dc.contributor.author	AbdulKareem, F B
dc.contributor.author	Adefuye, P O
dc.contributor.author	Musa, O
dc.contributor.author	Abudu, E K
dc.contributor.author	Agboola, A O J
dc.contributor.author	Banjo, A A F
dc.date.accessioned	2020-07-16T16:19:59Z
dc.date.available	2020-07-16T16:19:59Z
dc.date.issued	2017
dc.description.abstract	Tamoxifen is the primary hormonal therapy for breast cancer as well as its chemoprevention. It is used in the management of breast cancer because of its anti oestrogenic effect. It is however an agonist on the endometrium with undesirable effects of endometrial proliferation with the risk of endometrial hyperplasia and carcinoma. Several authors have reported cases of endometrial hyperplasia and carcinoma following tamoxifen therapy for breast carcinoma. No such report has been made from Nigeria . This paper presents the first case of endometrial carcinoma following tamoxifen therapy for breast carcinoma in a 52 year old Nigerian female. It also highlights the recommended guidelines for the follow up of women with breast cancer on tamoxifen therapy.	en_US
dc.identifier.citation	Niger Postgrad Med J . 2007 Dec;14(4):355-7.	en_US
dc.identifier.uri	https://ir.unilag.edu.ng/handle/123456789/8626
dc.language.iso	en	en_US
dc.publisher	Nigerian Postgraduate Medical Journal	en_US
dc.title	Endometrial Carcinoma Following Treatment for Breast Carcinoma in a Nigerian Female. A Case Report and Review of the Literature	en_US
dc.type	Article	en_US

Now showing 1 - 1 of 1

Name:: Endometrial Carcinoma Following Treatment for Breast Carcinoma in a Nigerian Female. A Case Report and Review of the Literature .png
Size:: 63.03 KB
Format:: Portable Network Graphics
Description:: Main article

Now showing 1 - 1 of 1